Schuman J S
New England Eye Center, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Clin Ther. 2000 Feb;22(2):167-208. doi: 10.1016/S0149-2918(00)88478-7.
Much experience has been gained with the use of older classes of antiglaucoma agents--topical beta-adrenergic-receptor antagonists, nonselective adrenergic-receptor agonists, oral carbonic anhydrase inhibitors, and cholinergic agents. In the past decade, new drugs and classes of drugs used to treat glaucoma have become available, including topical carbonic anhydrase inhibitors, prostaglandin analogues, and alpha2-adrenergic-receptor agonists. Extensive community-based use of antiglaucoma medications has led to an increased understanding of the acute and long-term safety and tolerability issues associated with their use.
This paper reviews the side effects associated with the various classes of topical antiglaucoma drugs, with a particular focus on long-term safety issues.
在使用 older classes of antiglaucoma agents(旧类抗青光眼药物)方面已积累了很多经验,这些药物包括局部β-肾上腺素能受体拮抗剂、非选择性肾上腺素能受体激动剂、口服碳酸酐酶抑制剂和胆碱能药物。在过去十年中,用于治疗青光眼的新药和新类别药物已面市,包括局部碳酸酐酶抑制剂、前列腺素类似物和α2-肾上腺素能受体激动剂。基于社区的抗青光眼药物广泛使用,使得人们对与其使用相关的急性和长期安全性及耐受性问题有了更多了解。
本文回顾了各类局部抗青光眼药物相关的副作用,尤其关注长期安全性问题。